Introduction {#S1}
============

Stress cardiomyopathy (SCM) is a unique form of heart disease that primarily affects women. Described in 1990 by Sato and colleagues, it is now recognized as accounting for 5.9--7.5% of women presenting to the emergency department with acute coronary syndromes ([@B1]--[@B4]). Although the prognosis is typically good, complications such as heart failure, arrhythmias, and thromboembolic phenomena do occur ([@B5]). Recent studies have shown that SCM patients have increased long-term morbidity and mortality (5.6% risk of death per patient year) ([@B6]--[@B8]). Therefore, this disorder may not be as benign as previously thought.

After almost 30 years of study, the mechanism of SCM is still not understood. Plasma concentrations of norepinephrine, epinephrine, and dopamine are twofold higher than those of AMI ([@B9]). Myocardial biopsy in SCM reveals inflammation and myocyte contraction band necrosis, which are features of catecholamine excess ([@B9]). In contrast, acute myocardial infarction (AMI) has greater myocyte necrosis ([@B10]). Despite these different mechanisms of injury, cardiac function is impaired to an equivalent degree in both conditions ([@B11]). The exact mechanism by which LV dysfunction occurs in SCM remains poorly understood.

Due to the presenting signs and symptoms, patients with SCM are referred for urgent coronary angiography, which reveals the absence of atherosclerotic plaque rupture. Coronary angiography exposes the SCM patient to unnecessary risk without therapeutic benefit. A biomarker that could differentiate between AMI and SCM would be useful, allowing for the identification of low risk SCM patients in whom angiography could be avoided. This would be especially helpful in patients with "secondary" SCM ([@B5]). "Secondary SCM" frequently occurs in medical intensive care units and is precipitated by critical illnesses such as sepsis ([@B12]). Due to the severity of illness in these cases, cardiac interventions such as coronary angiography or the initiation of antiplatelet therapy are often deferred.

There have been no studies examining novel protein biomarkers in SCM. A ratio of serum B-type natriuretic peptide to troponin I (TnI) ≥1,272 is highly specific for SCM (95%) but has limited sensitivity (52%) ([@B13]). Soluble suppression of tumorigenicity 2 has been studied to identify SCM in medical intensive care units ([@B12]). A circulating profile of plasma microRNAs (miR-16, mir-26a, miR-1, and miR-133a) has shown good sensitivity and specificity for SCM ([@B14]). However, the use of plasma microRNAs for diagnostic purposes has not been adopted in clinical practice ([@B15]). Furthermore, these studies shed no light into the biologic differences between these two syndromes.

We hypothesized that there would be differences between circulating proteins in SCM and AMI that might elucidate the underlying mechanisms. Therefore, the purpose of our study was twofold. The first aim was to perform an unbiased comparison of circulating proteins in SCM and AMI in order to provide insight into the pathophysiology of SCM. Our second aim was to identify putative protein biomarkers of SCM.

In order to achieve these aims, we utilized recently described DNA aptamer technology to perform our screen (SOMAscan V1.3K, SOMAlogics) ([@B16]--[@B18]). This assay uses single stranded DNA aptamers to specifically bind 1,310 predetermined proteins in a single sample. The advantages of this technology include higher throughput and precision than traditional proteomic methods such as mass spectrometry or antibody based methods ([@B16], [@B17]).

Using this assay, we found that women presenting with either SCM or AMI have an increase in proteins related to complement, coagulation, and inflammation. The unexpected and profound activation of inflammatory and pro-thrombotic pathways in SCM may contribute to the increased risk of mortality attributed to this disorder ([@B7], [@B8]).

Materials and Methods {#S2}
=====================

Patient Enrollment {#S2-1}
------------------

Women who presented with non-ST or ST elevation myocardial infarction and had coronary angiography demonstrating either culprit LAD disease or apical variant SCM were prospectively enrolled. Detailed presenting features of the AMI group are shown in Table [1](#T1){ref-type="table"}. We specifically limited our study to patients with culprit LAD disease and apical SCM in order to control for the differences between echocardiograms and clinical features that have been demonstrated with variants of SCM ([@B19]). All of the SCM patients met the Mayo Clinic Criteria for SCM ([@B20]). The normal control group for proteomic analyses consisted of 6 subjects (3 females, 3 males) with a mean age of 51.33 ± 10.11 years. They were healthy ambulatory persons without diabetes, hyperlipidemia, hypertension, or known coronary disease and taking no prescription medications. Written informed consent was obtained according to protocol \#00000941 as approved by the University of Massachusetts Medical School IRB.

###### 

Angiographic characteristics of acute myocardial infarction group.

  Patient   Culprit lesion             Flow     Presentation   Onset of pain (h)   Peak troponin I (ng/ml)   Treatment
  --------- -------------------------- -------- -------------- ------------------- ------------------------- -----------
  1         100% pLAD                  TIMI 0   STEMI          10                  90.0                      1 DES
  2         90% pLAD ulcerated                  NSTEMI                             1.84                      1 DES
  3         95% mLAD ulcerated         TIMI 3   STEMI          \>48                33.7                      2 DES
  4         pLAD dissection            TIMI 3   STEMI          4                   20.2                      None
  5         pLAD 40%, possible spasm   TIMI 3   NSTEMI         10                  10.8                      None
  6         pLAD 80%, hazy             TIMI 3   NSTEMI         2                   1.21                      1 DES
  7         pLAD 80%                   TIMI 2   NSTEMI                             13.8                      1 DES
  8         D1, 95%                    TIMI 2   STEMI          4                   35.7                      POBA D1
  9         pLAD 99%, thrombus         TIMI3    STEMI          \>48                70.0                      1 DES
  10        pLAD 99%, thrombus                  STEMI          10                  13.0                      1 DES
  11        pLAD 95%                   TIMI 2   STEMI          \>48                8.0                       1 DES
  12        pLAD 95%, hazy                      STEMI          1                   70.0                      1 DES

Serum Isolation and Proteomic Analysis {#S2-2}
--------------------------------------

Non-fasting venous blood was drawn (after cardiac catheterization but within 24 h of presentation) into SST tubes, spun, and frozen at −80°C. Acute samples were analyzed in 12 AMI patients and 15 SCM patients. Follow-up samples were drawn in clinic at 2 weeks follow-up (AMI *n* = 4, SCM *n* = 11). We chose to sample blood at 2 weeks follow-up because this is the median time to recovery of LV function in SCM ([@B9]). Samples were shipped to an outside laboratory on dry ice where assays were performed using SOMAscan reagents according to the manufacturer's protocol ([@B16]). The menu of the 1,310 protein aptamers included in the assay is available online.[^1^](#fn1){ref-type="fn"} The median intra-assay and inter-assay coefficient of variation was 2.1%.

Echocardiography {#S2-3}
----------------

Complete 2D echocardiograms were performed within 24 h of presentation and in follow-up (2 weeks) in patients with AMI and SCM. Ejection fraction, 2D volumes, and linear dimensions were measured according to ASE guidelines ([@B21]).

Statistical Methods {#S2-4}
-------------------

Somalogics SOMAScan technology was used to measure levels of 1,310 predetermined proteins included in the assay (see text footnote 1) in 48 patient samples using 1,310. Protein expression levels were expressed as normalized counts \[relative fluorescent units (RFUs)\] for the 48 patient samples. Data were analyzed using Somalogics' SomaSuite software (version 1.0.3a). The non-parametric two-sided Mann--Whitney *U*-test was used to analyze the normalized expression levels, to determine statistically significant differentially expressed proteins for each pairwise group comparison. The *p*-value, *q*-value, and other statistics were calculated for each protein. The *q*-values are calculated using the false discovery rate (FDR) method ([@B22]). The fold change values for each pairwise comparison are computed on the average values in the log2 scale. Statistically differentially expressed proteins were defined if the following criteria are met (absolute log2-fold change \>1; *q* \< 0.05). The raw data for this study were deposited in the Gene Expression Omnibus and can be downloaded at <https://www.ncbi.nlm.nih.gov/geo/info/linking.html> (Accession GSE95368).

In order to determine signaling pathways altered in each condition, functional enrichment analysis was carried out using the WEB-based GEne SeT AnaLysis Toolkit (Webgestalt) ([@B23]). The Kyoto Encyclopedia of Genes and Genomes database was selected for enrichment analysis, with the proteome selected as the reference set. The hypergeometric test was used for enrichment evaluation for the lists of statistically differentially expressed proteins. The Benjamini and Hochberg method was used to calculate the adjusted *p*-values (*q*) and the significance cutoff filter was set to *q* \< 0.05 ([@B24]).

The complex heatmap package (version 1.12.0) was used to generate a heatmap (Figure [1](#F1){ref-type="fig"}) and the following parameters were used (clustering distance rows = "maximum," clustering method rows = "ward.D") ([@B25]). By determining if a protein was differentially expressed in one or more of the 10 possible comparisons (Figure [1](#F1){ref-type="fig"}), a list of proteins of interest was curated. This list comprising 64 proteins, together with the protein expression levels averaged for each protein in each of the medical conditions, was used as input to generate a heatmap. Five clusters are generated; for each cluster, the members were identified (Figure [1](#F1){ref-type="fig"}).

![The heatmap shows the serum protein expression in the five groups \[normal, the acute myocardial infarction conditions (AMI, AMI_Post) and the stress cardiomyopathy conditions (SCM, SCM_Post)\]. By determining if a protein was differentially expressed in one or more of the ten possible comparisons, a list of 64 proteins was generated. Differentially regulated proteins were defined using the following filters (absolute log2 fold change \>1; *q* \< 0.05). The average level of each protein, in each of these conditions, was used to generate the heat-map. Bright red is increased expression, and deep purple is decreased expression (*Z*-score). For example, concentrations of N-terminal pro-BNP (cluster 3) are increased in AMI and SCM compared to normal.](fcvm-04-00049-g001){#F1}

Results {#S3}
=======

Clinical Characteristics {#S3-1}
------------------------

The baseline clinical and echocardiographic characteristics are shown in Tables [1](#T1){ref-type="table"}--[3](#T3){ref-type="table"}. Compared to AMI, women with SCM had lower systolic and diastolic blood pressure on admission (112.2 ± 16.5 vs. 126.3 ± 21.9 and 66.4 ± 12.1 vs. 74.8 ± 11.6 mm Hg, *p* \< 0.05 for both). Left ventricular end diastolic pressure was elevated in both groups (18.7 ± 9.4 vs. 14.9 ± 14.3 mm Hg, *p* = 0.36). Women with AMI had higher peak values of TnI (32.03 ± 29.46 vs. 2.68 ± 2.6 ng/ml, *p* \< 0.05) and CPK (1,206 ± 1,348 vs. 104 ± 63.5 ng/ml, *p* \< 0.05) during their hospitalization.

###### 

Clinical characteristics of study participants.

                              Acute myocardial infarction (*n* = 16)   Stress cardiomyopathy (*n* = 26)   *p-*Value
  --------------------------- ---------------------------------------- ---------------------------------- -----------
  Age (years)                 57.87 ± 16.0                             65.08 ± 9.11                       0.12
  Height (cm)                 158.2 ± 5.8                              162.1 ± 6.5                        0.06
  Weight (kg)                 72.3 ± 16.2                              72.8 ± 11.6                        0.90
  BSA (m^2^)                  1.7 ± 0.1                                1.7 ± 0.14                         0.55
  Presenting HR (bpm)         80.3 ± 15.9                              84.1 ± 14.1                        0.43
  Presenting SBP (mm Hg)      126.3 ± 21.9                             112.2 ± 16.5                       *\<0.05*
  Presenting DBP (mm Hg)      74.8 ± 11.6                              66.4 ± 12.1                        *\<0.05*
  HDL (mg/dl)                 55.2 ± 36.6                              61.3 ± 25.8                        0.57
  Total cholesterol (mg/dl)   182.4 ± 50.1                             172.7 ± 40.8                       0.54
  LDL (mg/dl)                 108.5 ± 44.2                             92.5 ± 32.2                        0.23
  Peak troponin (ng/ml)       32.0 ± 29.4                              2.6 ± 2.6                          *\<0.05*
  Peak CPK (ng/ml)            1,206.0 ± 1,348                          104.5 ± 63.5                       *\<0.05*
  LVEDP (mm Hg)               14.9 ± 14.3                              18.7 ± 9.4                         0.36
  Emotional stress trigger    0 (0%)                                   13 (52%)                           *\<0.001*
  Chest pain                  14 (93%)                                 21 (84%)                           0.388
  Shortness of breath         6 (40%)                                  11 (44%)                           0.804
  Syncope                     0 (0%)                                   2 (8%)                             0.261
  Rales                       3 (20%)                                  0 (0%)                             *\<0.05*
  JVD                         2 (13%)                                  0 (0%)                             0.061
  S3 or S4                    1 (7%)                                   0 (0%)                             0.191
  Peripheral edema            4 (27%)                                  2 (8%)                             0.109
  Beta blockers               3 (25%)                                  8 (32%)                            0.411
  Calcium channel blockers    1 (7%)                                   5 (20%)                            0.253
  ACEi/ARBs                   3 (25%)                                  11 (44%)                           0.123
  Diuretics                   3 (25%)                                  6 (24%)                            0.769
  Statins                     1 (7%)                                   11 (44%)                           *\<0.05*
  ASA                         4 (27%)                                  9 (36%)                            0.542
  SSRI                        3 (18%)                                  9 (34%)                            0.282
  Hypertension                6 (40%)                                  17 (68%)                           0.083
  Diabetes mellitus           3 (25%)                                  5 (20%)                            0.281
  Smoking history             8 (53%)                                  8 (32%)                            0.182
  Depression/anxiety          6 (40%)                                  14 (56%)                           0.327

*BSA, body surface area; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CPK, creatinine phosphokinase; LVEDP, left ventricular end-diastolic pressure; JVD, jugular venous distension; S3 or S4, third or fourth heart sound, respectively; ACEi/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; ASA, aspirin; SSRI, selective serotonin reuptake inhibitor*.

*Values are mean ± SD or *n* (%). Italicized p values are statistically significant*.

###### 

Acute and recovery echocardiographic data.

                      Acute myocardial infarction (*n* = 11)   Stress cardiomyopathy (*n* = 15)   *p*-Value
  ------------------- ---------------------------------------- ---------------------------------- -----------
  **Acute**                                                                                       
  EF (%)              39 ± 12                                  37 ± 12                            0.479
  LAVI (ml/m^2^)      33.1 ± 7.1                               27.25 ± 6.0                        *\<0.05*
  LVMI (gm/m^2^)      81.55 ± 19.0                             82.95 ± 21.0                       0.53
  RWT                 0.38 ± 0.04                              0.41 ± 0.06                        0.51
  LVIDd (mm)          47.45 ± 5.99                             45.58 ± 6.54                       0.234
  LVIDs (mm)          34.11 ± 7.27                             30.05 ± 7.06                       *\<0.05*
  LVEDV (ml)          95.15 ± 25.67                            77.11 ± 23.70                      *\<0.001*
  LVESV (ml)          56.73 ± 25.19                            43.17 ± 12.94                      *\<0.01*
  LVEDVI (ml/m^2^)    54.50 ± 13.63                            45.53 ± 13.60                      *\<0.001*
  LVESVI (ml/m^2^)    32.34 ± 13.54                            24.41 ± 7.56                       *\<0.001*
  **Recovery**                                                                                    
  EF (%)              45 ± 13                                  60 ± 7                             *\<0.001*
  ΔEF (%)             +8 ± 13                                  +23 ± 12                           *\<0.001*
  LVIDd (mm)          49.91 ± 7.73                             45.50 ± 5.58                       *\<0.05*
  ΔLVIDd (mm)         +1.40 ± 8.11                             −0.21 ± 6.61                       0.450
  LVIDs (mm)          35.18 ± 8.30                             27.68 ± 4.82                       *\<0.001*
  ΔLVIDs (mm)         −1.37 ± 7.46                             −2.54 ± 5.17                       0.529
  LVEDV (ml)          99.88 ± 36.93                            75.50 ± 18.93                      *\<0.001*
  ΔLVEDV (ml)         +5.77 ± 26.9                             −3.20 ± 25.40                      0.320
  LVESV (ml)          58.82 ± 34.09                            34.81 ± 13.67                      *\<0.001*
  ΔLVESV (ml)         +1.25 ± 13.34                            −10.60 ± 15.70                     *\<0.05*
  LVEDVI (ml/m^2^)    57.38 ± 18.57                            45.50 ± 11.28                      *\<0.001*
  ΔLVEDVI (ml/m^2^)   +1.71 ± 15.38                            −0.32 ± 14.03                      0.917
  LVESVI (ml/m^2^)    33.43 ± 17.87                            19.63 ± 7.17                       *\<0.001*
  ΔLVESVI (ml/m^2^)   +2.03 ± 13.19                            −4.95 ± 9.7                        *\<0.05*

*EF, ejection fraction; LAVI, left atrial volume index; LVMI, left ventricular mass index; RWT, relative wall thickness; LVIDd, left ventricular internal dimension diastolic; LVIDs, left ventricular internal dimension systolic; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic volume; LVEDVI, left ventricular end diastolic volume index; LVESVI, left ventricular end systolic volume index; ΔEF (%), change in ejection fraction; ΔLVIDd, change in left ventricular internal dimension diastolic; ΔLVIDs, change in left ventricular internal dimension systolic; ΔLVEDV, change in left ventricular end diastolic volume; ΔLVESV, change in left ventricular end systolic volume; ΔLVEDVI, change in left ventricular end diastolic volume index; ΔLVESVI, change in left ventricular end systolic volume index*.

*Values are mean ± SD or *n* (%). Italicized p values are statistically significant*.

Echocardiographic Characteristics {#S3-2}
---------------------------------

Stress cardiomyopathy and AMI patients had equivalent reductions in systolic function \[LVEF (%)\] in the acute phase (37 ± 12 vs. 39 ± 12, *p* = 0.47) (Table [3](#T3){ref-type="table"}). However, SCM patients had smaller indexed left ventricular systolic (LVESVI 24.41 ± 7.56 vs. 32.34 ± 13.54 ml/m^2^, *p* \< 0.001) and diastolic (LVEDVI 45.53 ± 13.60 vs. 54.50 ± 13.63 ml/m^2^, *p* \< 0.001) volumes than AMI. SCM patients also had a greater indexed left atrial volume than AMI (LAVI 33.1 ± 7.7 vs. 27.25 ± 6.0, *p* \< 0.05).

Stress cardiomyopathy patients had a significantly greater improvement in LV systolic function in follow-up, as shown by the mean LVEF (%) (60 ± 7 vs. 45 ± 13, *p* \< 0.001), interval change in ΔLVEF (%) (+23 ± 12 vs. +8 ± 13, *p* \< 0.001), and interval reduction in LVESVI (ΔLVESVI −4.95 ± 9.7 vs. +2.0 ± 13.19 ml/m^2^, *p* \< 0.05).

Proteomic Analyses {#S3-3}
------------------

There were no proteins differentially expressed (absolute log2-fold change \>1; *q* \< 0.05) between AMI and SCM in the acute phase (Table [4](#T4){ref-type="table"}). This was true even when we lowered the threshold for differential regulation to *q* \< 0.05 with any fold change (Table [4](#T4){ref-type="table"}). When we compared normal controls vs. AMI, there were 35 proteins with differential expression (absolute log2-fold change \>1; *q* \< 0.05) (Figure [1](#F1){ref-type="fig"}; Table [4](#T4){ref-type="table"}). In the normal vs. SCM comparison, 45 proteins were differentially regulated (absolute log2-fold change \>1; *q* \< 0.05) (Figure [1](#F1){ref-type="fig"}; Table [4](#T4){ref-type="table"}).

###### 

Number of differentially expressed (DE) proteins between pairwise comparisons.

  Conditions compared                            Number of DE proteins with *q* \< 0.05 (absolute log2-fold change ignored)   Number of DE proteins with absolute log2-fold change \>1; *q* \< 0.05   Number of DE proteins with absolute log2-fold change \>1; *q* \< 0.05   Number of DE proteins with absolute log2-fold change \>1; *q* \< 0.05
  ---------------------------------------------- ---------------------------------------------------------------------------- ----------------------------------------------------------------------- ----------------------------------------------------------------------- -----------------------------------------------------------------------
  Normal vs. acute myocardial infarction (AMI)   98                                                                           35                                                                      17                                                                      18
  AMI vs. AMI post                               0                                                                            0                                                                       0                                                                       0
  Normal vs. AMI post                            0                                                                            0                                                                       0                                                                       0
  Normal vs. stress cardiomyopathy (SCM)         124                                                                          45                                                                      22                                                                      23
  SCM vs. SCM post                               0                                                                            0                                                                       0                                                                       0
  Normal vs. SCM post                            159                                                                          46                                                                      17                                                                      29
  AMI vs. SCM                                    0                                                                            0                                                                       0                                                                       0
  AMI vs. SCM post                               40                                                                           4                                                                       1                                                                       3
  SCM vs. AMI post                               0                                                                            0                                                                       0                                                                       0
  AMI post vs. SCM post                          0                                                                            0                                                                       0                                                                       0

Most of the proteins were commonly differentially regulated in both SCM and AMI compared to controls \[Figure [1](#F1){ref-type="fig"} (cluster 4), Figure [2](#F2){ref-type="fig"}; Table [5](#T5){ref-type="table"}\]. However, there were four candidate proteins that tended to be increased in acute SCM compared to AMI and controls. These proteins were kynureninase (KYNU), K7, follistatin-like 3, and netrin-1 (NET1) \[Figure [1](#F1){ref-type="fig"} (cluster 3); Table [5](#T5){ref-type="table"}\].

![Venn diagram showing differential and overlapping protein expression between the conditions compared (Table [4](#T4){ref-type="table"}). As shown in the middle of the diagram, 30 (7**+**21**+**2) proteins are commonly differentially regulated in AMI and SCM compared to normal controls. Specific proteins from Venn diagram subsections are listed in Table [5](#T5){ref-type="table"}.](fcvm-04-00049-g002){#F2}

###### 

Specific proteins from Venn diagram subsection.

  Venn diagram segment                                                           Proteins
  ------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------
  2 proteins exclusively in acute myocardial infarction (AMI) vs. normal         HAMP, FGG
  6 proteins exclusively in stress cardiomyopathy (SCM) vs. normal               C3, F5, FSTL3, Netrin-1, PLAT, THBS2
  12 proteins exclusively in SCM post vs. normal                                 PGD, MYC, CTSD, GRB2, HIST2H2BE, HIST1H3A, IL9, JAK2, Kynureninase, MST1, SERPINA5, PIK3CA/PIK3R1
  1 protein exclusively in AMI vs. SCM post                                      HPX
  7 common proteins in AMI vs. normal and SCM vs. normal                         NAMPT, F9, F9ab, HGF, GDF-15, ITGA1/ITGB1, MBL2
  1 common protein in SCM post vs. normal and AMI vs. SCM post                   KLK7
  3 common proteins in AMI vs. normal and SCM post vs. normal                    XPNPEP1, PTPN6, CRYZL1
  21 common elements in AMI vs. normal, SCM vs. normal and SCM post vs. normal   C3, LTA4H, C3a, iC3b, APOB, IL36A, C4A/C4B, ALB, EHMT2, MFGE8, F2, A2M, PRKACA, KLK3, RXFP1, APOE4, APOE3, PKM2, APOE, GAPDH, NPPB
  9 common elements in SCM vs. normal and SCM post vs. normal                    ARTN, AZU1, CA13, ELANE, FABP3, FTCD, ITGA2B/ITGB3, HNRNPK, SFRP1
  2 common elements in AMI vs. normal, SCM vs. normal, and AMI vs. SCM post      CRP, TNNI3

The heat map (Figure [1](#F1){ref-type="fig"}) and bar plots of significantly altered proteins (Figures S1 and S2 in Supplementary Material) demonstrated the expected rise and fall of traditional markers of necrosis (TNNI3, CK-MB), inflammation (CRP), and wall stress (NPPB) in the acute and follow-up phase. There was a strong positive correlation between the hospital laboratory measured peak TnI (nanogram per milliliter) and the SOMAscan measured TnI (RFU) (ρ = 0.79, *p* \< 0.001) (Figure [3](#F3){ref-type="fig"}).

![SOMAscan measured troponin correlates well with hospital-based measurement. There was a strong and significant correlation between peak troponin I (TnI) (ng/ml) measured in the hospital laboratory and the TnI \[relative fluorescent units (RFU)\] as measured by SOMAscan. Open circles represent peak TnI in stress cardiomyopathy (SCM) patients (*n* = 15) and black triangles represent peak TnI in acute myocardial infarction (AMI) patients (*n* = 12).](fcvm-04-00049-g003){#F3}

Pathway analysis of the differentially regulated proteins in each group revealed a large degree of similarity (Tables [6](#T6){ref-type="table"} and [7](#T7){ref-type="table"}). The complement and coagulation pathway displayed the greatest enrichment ratio in both groups (Tables [6](#T6){ref-type="table"} and [7](#T7){ref-type="table"}). There was significant overlap among other inflammatory pathways, nine of which were commonly increased in SCM and AMI. Several pathways were unique to SCM: focal adhesion, extracellular matrix--receptor interaction, malaria, regulation of actin cytoskeleton, arrythmogenic right ventricular cardiomyopathy, axon guidance, and Wnt signaling (Table [7](#T7){ref-type="table"}).

###### 

KEGG pathway enrichment analysis: normal vs. acute myocardial infarction.

  KEGG pathway                          Proteins                    Enrichment ratio   Adj. *p*-value
  ------------------------------------- --------------------------- ------------------ ----------------
  Complement and coagulation cascades   C4B, C3, FGG, F2, F9, A2M   150.87             \<0.001
  *Staphylococcus aureus* infection     MBL2, C4B, C3, FGG          108.16             \<0.001
  Leshmaniasis                          C3, PTPN6, ITGB1            61.96              \<0.001
  Dilated Cardiomyopathy                TNNI3, PRKACA, ITGB1        49.57              \<0.001
  Phagosome                             MBL2, C3, ITGB1             29.16              \<0.001
  Pathways in cancer                    HGF, KLK3, ITGB1            13.69              \<0.05
  Hypertrophic cardiomyopathy           TNNI3, ITGB1                35.83              \<0.05
  Systemic lupus erythematosus          C3, C4B                     21.87              \<0.05
  Alzheimer's disease                   APOE, GAPDH                 17.81              \<0.05

*KEGG, Kyoto Encyclopedia of Genes and Genomes*.

###### 

KEGG pathway enrichment analysis: normal vs. stress cardiomyopathy.

  KEGG pathway                                      Proteins                         Enrichment ratio   Adj. *p*-value
  ------------------------------------------------- -------------------------------- ------------------ ----------------
  Complement and coagulation cascades               C3, C4B, F2, A2M, F9, PLAT, F5   131.59             \<0.001
  Phagosome                                         MLB2, C3, THBS2, ITGB3, ITGB1    37.09              \<0.001
  Dilated cardiomyopathy                            TNNI3, PRKACA, ITGB3, ITGB1      50.44              \<0.001
  *Staphylococcus aureus* infection                 C3, C4B                          61.90              \<0.001
  Focal adhesion                                    THBS2, HGF, ITGB3, ITGB1         22.70              \<0.001
  Hypertrophic cardiomyopathy                       TNNI3, ITGB3, ITGB1              41.02              \<0.001
  ECM--receptor interaction                         THBS2, ITGB3, ITGB1              40.06              \<0.001
  Systemic lupus erythematosus                      C3, C4B, ELANE                   25.04              \<0.01
  Malaria                                           HGF, THBS2                       44.51              \<0.01
  Regulation of actin cytoskeleton                  F2, ITGB3, ITGB1                 15.98              \<0.01
  Arrhythmogenic right ventricular cardiomyopathy   ITGB3, ITGB1                     30.67              \<0.01
  Leishmaniasis                                     C3, ITGB1                        31.53              \<0.01
  Pathways in cancer                                HGF, KLK3, ITGB1                 10.44              \<0.01
  Axon guidance                                     Netrin-1, ITGB1                  17.60              \<0.05
  Wnt signaling pathway                             SFRP1, PRKACA                    15.30              \<0.05
  Alzheimer's disease                               APOE, GAPDH                      13.59              \<0.05

*KEGG, Kyoto Encyclopedia of Genes and Genomes*.

Discussion {#S4}
==========

Although the pathophysiology, natural history, and outcomes of AMI and SCM are different, they do share common features. First, both are characterized by acutely decreased cardiac function ([@B11]). Second, each condition can be complicated by heart failure, arrhythmia, or thromboembolic events. Due to these similarities, women presenting with SCM are often referred for coronary angiography ([@B5]). However, in low risk cases, and in cases of "secondary SCM," a biomarker would be useful. One of the aims of our study was to discover putative biomarkers of SCM; we identified four candidates (FSTL3, Kallikrein7, KYNU, and NET1). A second aim was to learn about the pathophysiology of SCM by comparing serum proteins to normal patients and those with AMI. We were surprised to find no differences between SCM and AMI in the acute phase. Both conditions were characterized by a robust increase in proteins related to inflammation, coagulation, and complement.

The characteristics of both study groups were consistent with prior studies. Patients with AMI had a greater peak TnI and a lower LVEF (%) on follow-up ([@B7], [@B9], [@B11]). SCM patients had smaller indexed LV diastolic and systolic volumes in both the acute and recovery phase. SCM patients had normalization of their systolic function in recovery, as demonstrated by a greater increase in LVEF (%) (Table [2](#T2){ref-type="table"}).

In regards to our proteomic analysis, we wish to emphasize that the SOMAscan 1.3 K measures a predetermined panel of 1,310 proteins, which is only 6.5% of the approximately 20,000 protein encoding genes in the genome. Therefore, there are many changes that were undetected by our assay. For example, tissue inhibitor of metalloproteinase 4 has previously been shown to be increased in SCM compared to AMI ([@B26]). However, tissue inhibitor of matrix metalloproteinase (TIMP)-4 specific aptamers were not included in the version of the SOMAscan that we used; therefore, this difference was not detected. Of the proteins that were included, many were commonly elevated in both AMI and SCM, particularly those related to complement, coagulation, and innate immunity. This was unexpected, as the degree of myocardial necrosis in SCM is less than in AMI ([@B7], [@B9]). The trigger for this acute inflammatory response remains unclear.

Complement is an arm of the innate immune system that aids in the detection and clearance of self and bacterial antigens ([@B27]). It was demonstrated in 1990 that complement is activated in AMI ([@B27]). This is the first report of complement activation in SCM. Local hypoxia may play a role in complement activation and neutrophil chemoattraction to sites of ischemia ([@B27]). Complement activation can trigger endothelial adhesion molecule expression, and subsequent leukocyte rolling, arrest, and diapedesis. It is notable that there are several small studies indicating that patients with SCM have greater endothelial dysfunction than those with AMI even in the subacute phase ([@B28]--[@B30]). This dysfunction could be due to low-level complement activation, increased leukocyte adhesion, and release of reactive oxygen species.

Complement is known to interact with the coagulation cascade ([@B27]). The increased levels of coagulation factor V (F5) and tissue plasminogen activator (PLAT, tPA) in SCM indicate that a pro-thrombotic state may be present. Patients with SCM have inducible hyperviscosity and there are multiple reports of increased thromboembolic events in the acute phase of SCM ([@B31]--[@B33]).

Several candidate proteins demonstrated a non-significant trend to be increased in acute SCM compared to AMI and controls \[NET1, FSTL3, kallikrein 7 (KLK7), KYNU\] (Figure [1](#F1){ref-type="fig"}, cluster 3). Netrin-1 is a neuronal growth factor that was originally reported in 1991 ([@B34]). NET1 promotes endothelial cell nitric oxide production and cell growth and migration *in vitro via* the receptor deleted in colorectal cancer (DCC) ([@B35]). NET1 has also been shown to reduce infarct size in mice ([@B36]). There is interest in using NET1 for the treatment of postischemic conditioning in AMI.

Follistatin-like 3 (FSTL3) was increased in SCM compared to controls. FSTL3 inhibits transforming growth factor beta (TGFβ) signaling ([@B37]). FSTL3 is upregulated in the myocardium and endothelium of failing human hearts ([@B38]). Cardiac specific ablation of FSTL3 reduces cardiac hypertrophy and fibrosis in response to transverse aortic constriction ([@B37]). FSTL3 may contribute to myocyte hypertrophy in response to stress stimuli, and the increased levels of FSTL3 in SCM may promote cardiac hypertrophy and fibrosis. This is consistent with prior data demonstrating that SCM has a matrix metalloproteinase (MMP)/tissue inhibitor of matrix metalloproteinase (TIMP) profile similar to hypertensive heart disease, which is distinct from AMI ([@B26]). We observed the same MMP/TIMP profile in our study (data not shown); however, the differences did not reach statistical significance. This is likely because the prior study used ELISA to measure MMP/TIMPs ([@B26]).

Kynureninase is an enzyme involved in tryptophan metabolism. It degrades 3-hydroxy kynurenine to 3-hydroxyanthranillic acid ([@B39]). Kynurenine is an endothelium-derived relaxation factor induced in sepsis ([@B40]). Whether or not KYNU is truly elevated in SCM will be the topic of future studies. Finally, KLK7 is a serine proteinase belonging to the human kallikrein gene family, of which there are 15 members ([@B41]). The kallikrein system is broadly expressed and has also been demonstrated to play a role in cardiac remodeling ([@B42]).

Limitations {#S4-1}
-----------

We acknowledge that our study has a small sample size and this may lead to false negative results. The AMI group included patients with both infarction and ischemia; this led to a large SD in the peak TnI value for the AMI group (Table [1](#T1){ref-type="table"}). Differences in medications given during the hospital stay may have influenced our results, in particular, the administration of heparin ([@B17]). The majority of our study participants were Caucasian women; therefore, the applicability of other races is limited. Many of our patients are referred from outside hospitals and were not available for the follow-up blood draw and echocardiogram. Unfortunately, we could not run the SOMAscan on all our samples due to cost limitations. Despite these limitations, we feel that our observations are original and make an important contribution to the literature.

Conclusion {#S5}
==========

In summary, despite different pathophysiologic mechanisms, the circulating proteome of AMI and SCM is similar. Activation of complement and coagulation pathways in SCM has not been previously reported and highlights the pro-thrombotic and inflammatory state of acute SCM. The stimulus for inflammation in SCM is unclear and will be the subject of future investigation. NET1, FSTL3, and KYNU, and KLK7 are putative markers of SCM that require prospective validation.
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